Loading…
Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.
Develops RNA-interference (RNAi) drugs that silence disease-causing genes, with a lead cardiometabolic drug and multiple pharma partnerships.
Income today comes from partners: upfront and milestone payments, and eventually royalties, from drugmakers that license its RNAi (RNA-interference) technology for specific targets, while it develops its own cardiometabolic drugs. Spending is heavy because it also funds its own trials.
Moat: narrow (IP / patents, process know-how). A proprietary TRiM RNAi delivery platform generates a broad, partnered pipeline across many disease areas.
Headquarters: Pasadena, California, US · Founded: 1989 · Employees: 711
Size Arrowhead Pharmaceuticals (ARWR) is a United States Health Care company (Biotechnology) with a market value of $8.22B, the 869th largest of 3,117 United States companies the cockpit tracks. Shares closed at $58.16 on 6 Nov 2026.
Performance Over six months the shares fell 20.0%, against +14.8% for the median peer and -1.1% for the United States market (cap-weighted) — 3rd lowest of 21 in its peer set.
Growth Revenue grew 16.9% over the last twelve months (peer median +26.0%); the operating margin is -33.8% (peer median 12.3%).
Valuation It trades at 11.9× enterprise value to sales against a peer median of 9.4× (6th most expensive of 16).
Capital Return on invested capital runs 85.0 points below its cost of capital (10.7% WACC).
Credit Arrowhead Pharmaceuticals has 1 bond outstanding ($700M).
Short interest Short interest is 7.8% of the free float (15 Oct 2026).
Next results Next results expected around 12 Nov 2026 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $669M | $829M | $3.55M | $241M | $243M |
| Revenue growth | — | +23,258% | -99% | -1% | — |
| Gross profit | $644M | $806M | -$15.0M | $228M | $233M |
| EBITDA | -$201M | $122M | -$582M | -$193M | -$168M |
| Net income | -$320M | -$1.63M | -$599M | -$205M | -$176M |
| Free cash flow | -$75.1M | $157M | -$604M | -$331M | -$189M |
| Capital expenditure | $16.1M | $22.7M | $141M | $177M | $52.8M |
| Total debt | $1.38B | $734M | $852M | $383M | $81.6M |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g |
|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | $8.22B | -20% | +17% | -34% | 11.9× | n/a |
| Alnylam Pharmaceuticals ALNY | $20.9B | -47% | +56% | 20% | 4.0× | 0.9% |
| Ionis Pharmaceuticals IONS | $6.55B | -48% | -7% | -68% | 7.7× | n/a |
| Novartis NOVN.SW | $298B | +15% | -4% | 30% | 6.3× | 1.7% |
| Wave Life Sciences WVE | $664M | -53% | -35% | -321% | 3.9× | n/a |
| Silence Therapeutics PLC Sponsored ADR SLN | $1.23B | +184% | -97% | -10,478% | 1,889.5× | n/a |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | ARWR | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | -4.2% | -3.7% | 11th highest of 21 |
| 6-month return | -20.0% | +14.8% | 3rd lowest of 21 |
| Distance from 52-week high | -39.1% | -25.8% | 5th lowest of 21 |
| Revenue growth (TTM) | +16.9% | +26.0% | 4th lowest of 16 |
| Operating margin | -33.8% | 12.3% | 3rd lowest of 16 |
| EV / Sales | 11.9× | 9.4× | 6th most expensive of 16 |
| ROIC minus cost of capital | -85.0 pp | -0.7 pp | lowest of 15 |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | EV / Sales | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Arrowhead Pharmaceuticals ARWR | United States | $8.22B | -20% | +17% | -34% | 11.9× | n/a | n/a |
| Twist Bioscience TWST | United States | $7.95B | +112% | +19% | -32% | 18.2× | n/a | n/a |
| 10x Genomics TXG | United States | $7.72B | +174% | -4% | -14% | 11.8× | 41.8% | +16.6% |
| Genscript Biotech 1548.HK | Hong Kong | $8.81B | +96% | +53% | 12% | 9.9× | 36.5% | +19.8% |
| Krystal Biotech KRYS | United States | $8.92B | -2% | +26% | 48% | 17.1× | 11.9% | +26.0% |
| Caris Life Sciences CAI | United States | $7.13B | +56% | +85% | 15% | 6.9× | 18.7% | +85.4% |
| Axsome Therapeutics AXSM | United States | $6.96B | -39% | +54% | -19% | 7.9× | n/a | n/a |
| CG Oncology CGON | United States | $6.74B | +9% | +1,030% | -4,056% | 917.8× | n/a | n/a |
| Vaxcyte PCVX | United States | $10.1B | +21% | n/a | n/a | n/a | n/a | n/a |
| ALTEOGEN 196170.KS | South Korea | $10.3B | -46% | +61% | 53% | 43.0× | 29.8% | +38.5% |
| Immunovant IMVT | United States | $6.31B | +5% | n/a | n/a | n/a | n/a | n/a |
| Sichuan Kelun Pharmaceutical 002422.SZ | China | $10.8B | +30% | 0% | 9% | 3.9× | 7.2% | +2.3% |
| Kodiak Sciences KOD | United States | $6.24B | +142% | n/a | n/a | n/a | n/a | n/a |
| BioMarin Pharmaceutical BMRN | United States | $10.9B | +4% | +20% | 19% | 3.9× | 6.5% | +12.0% |
| Kymera Therapeutics KYMR | United States | $11.2B | +53% | +134% | -396% | 101.2× | n/a | n/a |
| Bio-Techne TECH | United States | $11.4B | +51% | 0% | 22% | 9.4× | 31.3% | +5.5% |
| Halozyme Therapeutics HALO | United States | $11.8B | +62% | +41% | 57% | 8.2× | 2.5% | +39.2% |
| Scholar Rock SRRK | United States | $5.72B | -3% | n/a | n/a | n/a | n/a | n/a |
| Hangzhou Tigermed Consulting 3347.HK | Hong Kong | $5.65B | -1% | +22% | 10% | 5.6× | 28.3% | +15.6% |
| Cogent Biosciences COGT | United States | $5.49B | -9% | n/a | n/a | n/a | n/a | n/a |
| Cspc Pharma 1093.HK | Hong Kong | $12.4B | +5% | +25% | 28% | 2.2× | -10.3% | +0.1% |
Arrowhead Pharmaceuticals has 1 bond outstanding with $700M face value.